# A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

> **NCT05932173** · PHASE1,PHASE2 · UNKNOWN · sponsor: **920th Hospital of Joint Logistics Support Force of People's Liberation Army of China** · enrollment: 60 (estimated)

## Conditions studied

- B-Cell Leukemia
- B-Cell Lymphoma
- B-cell Tumors

## Interventions

- **BIOLOGICAL:** Anti-CD19 Autologous CAR-T Cell Infusion

## Key facts

- **NCT ID:** NCT05932173
- **Lead sponsor:** 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05932173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05932173, "A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05932173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*